3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
2
Smoldering Multiple Myeloma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myeloid, Acute
1
Carcinoma, Squamous Cell
1
Interventions
Dexamethasone
20
Melphalan
13
Thalidomide
10
Bortezomib
10
Lenalidomide
8
Cyclophosphamide
8
Prednisone
6
Filgrastim
6
Doxorubicin
6
Vincristine
5
Epoetin Alfa
5
pomalidomide
3
Zoledronic Acid
3
Peripheral Blood Stem Cell Transplantation
3
Idarubicin
3
carfilzomib
2
Vorinostat
2
Radiotherapy
2
Interferon-alpha
2
Granulocyte Colony-Stimulating Factor
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Carmustine
2
Calcium Dobesilate
2
Busulfan
2
valspodar
1
sargramostim
1
oblimersen
1
liposomal doxorubicin
1
isatuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms, Plasma Cell
×
Maintenance
×
Clear all
NCT01554852
2018-06-11
Myeloma XI
University of Leeds
Phase 3
Unknown
4,420 enrolled